We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Vaccitech PLC | NASDAQ:VACC | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 4.75 | 4.76 | 0 | 01:00:00 |
Event: | Morgan Stanley 20th Annual Healthcare Conference 2022, New York City |
Date: | Monday, September 12 – Wednesday, September 14 |
Presentation: | Fireside Chat |
Time: | 1:40 – 2:10 p.m. EDT on Monday, September 12 |
Event: | H.C. Wainwright 24th Annual Global Investment Conference, New York City |
Date: | Monday, September 12 – Wednesday, September 14 |
Presentation: | Company Overview |
Time: | 10:30 a.m. EDT on Wednesday, September 14 |
Webcast: | Events section of the Vaccitech website |
Alongside the events listed above, the Company will participate in 1x1 investor meetings that can be booked with the relevant bank representatives or directly with the Company.
About Vaccitech plcVaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja Stout, Scius Communications (EU)Direct: +44 (0) 7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Georgy Egorov, CFO, VaccitechEmail: IR@vaccitech.co.uk
1 Year Vaccitech Chart |
1 Month Vaccitech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions